Symbols / ARMP $13.91 -6.01% Armata Pharmaceuticals, Inc.
ARMP Chart
About
Sources Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Stock Fundamentals
Scroll to Statements| Market Cap | 509.56M | Enterprise Value | 788.89M | Income | -173.80M | Sales | 4.90M | Book/sh | -6.00 | Cash/sh | 0.24 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | -8.86 |
| PEG | — | P/S | 103.91 | P/B | -2.32 | P/C | — | EV/EBITDA | -26.57 | EV/Sales | 160.87 |
| Quick Ratio | 1.02 | Current Ratio | 1.19 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -4.80 | EPS next Y | -1.57 |
| EPS Growth | — | Revenue Growth | -12.10% | Earnings | 2026-05-13 | ROA | -23.90% | ROE | — | ROIC | — |
| Gross Margin | -220.49% | Oper. Margin | -7.75% | Profit Margin | 0.00% | Shs Outstand | 36.63M | Shs Float | 11.27M | Short Float | 2.70% |
| Short Ratio | 9.69 | Short Interest | — | 52W High | 16.34 | 52W Low | 1.17 | Beta | 1.40 | Avg Volume | 47.24K |
| Volume | 63.42K | Target Price | $17.50 | Recom | Strong_buy | Prev Close | $14.80 | Price | $13.91 | Change | -6.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.50
Mean price target
2. Current target
$13.91
Latest analyst target
3. DCF / Fair value
$-13.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.91
Low
$15.00
High
$20.00
Mean
$17.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-01-05 | init | Jones Trading | — → Buy | $15 |
| 2025-05-19 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-08 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-22 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-03-07 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2021-03-22 | main | HC Wainwright & Co. | — → Buy | $7 |
| 2020-05-15 | reit | HC Wainwright & Co. | — → Buy | $5 |
| 2020-03-20 | reit | HC Wainwright & Co. | — → Buy | $9 |
| 2020-02-06 | init | Maxim Group | — → Buy | $8 |
| 2019-06-19 | init | Ladenburg Thalmann | — → Buy | $9 |
- Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN hu, 23 Apr 2026 01
- ARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors. - Retail Trader Ideas - UBND thành phố Hải Phòng hu, 23 Apr 2026 01
- Auditor flags going concern as Armata ends 2025 with $14.1M cash - Stock Titan Wed, 25 Mar 2026 07
- Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - PR Newswire hu, 19 Mar 2026 07
- Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - Yahoo Finance hu, 23 Oct 2025 07
- ARMP Forecast, Price Target & Analyst Ratings | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill Fri, 17 Apr 2026 07
- Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - The Globe and Mail Fri, 03 Apr 2026 07
- Armata surges on mid-stage trial data for antibacterial agent - Seeking Alpha Wed, 22 Oct 2025 07
- Armata Pharmaceuticals stock gains on FDA designation - Investing.com Mon, 23 Feb 2026 08
- Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan hu, 19 Mar 2026 07
- Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan ue, 17 Mar 2026 07
- Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Yahoo Finance Mon, 06 Oct 2025 07
- Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PR Newswire Wed, 12 Nov 2025 08
- Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia - PR Newswire ue, 13 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
31.22
-26.43%
|
42.44
+3.78%
|
40.89
+10.68%
|
36.95
|
| Research And Development |
|
23.72
-31.11%
|
34.43
+1.94%
|
33.77
-3.56%
|
35.02
|
| Selling General And Administration |
|
12.41
-5.88%
|
13.18
+13.18%
|
11.65
+56.64%
|
7.44
|
| General And Administrative Expense |
|
12.41
-5.88%
|
13.18
+13.18%
|
11.65
+56.64%
|
7.44
|
| Other Gand A |
|
12.41
-5.88%
|
13.18
+13.18%
|
11.65
+56.64%
|
7.44
|
| Other Operating Expenses |
|
-4.90
+5.22%
|
-5.17
-14.24%
|
-4.53
+17.77%
|
-5.51
|
| Total Expenses |
|
31.22
-26.43%
|
42.44
+3.78%
|
40.89
+10.68%
|
36.95
|
| Operating Income |
|
-31.22
+26.43%
|
-42.44
-3.78%
|
-40.89
-10.68%
|
-36.95
|
| Total Operating Income As Reported |
|
-36.63
+13.67%
|
-42.44
-3.78%
|
-40.89
-10.68%
|
-36.95
|
| EBITDA |
|
-155.68
-2173.00%
|
-6.85
+89.54%
|
-65.45
-81.67%
|
-36.02
|
| Normalized EBITDA |
|
-150.27
-1566.84%
|
-9.02
+85.36%
|
-61.58
-70.95%
|
-36.02
|
| Reconciled Depreciation |
|
1.53
+15.55%
|
1.32
+36.32%
|
0.97
+8.97%
|
0.89
|
| EBIT |
|
-157.21
-1823.28%
|
-8.17
+87.69%
|
-66.42
-79.91%
|
-36.92
|
| Total Unusual Items |
|
-5.41
-349.86%
|
2.17
+156.07%
|
-3.86
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-5.41
-349.86%
|
2.17
+156.07%
|
-3.86
|
0.00
|
| Special Income Charges |
|
-5.41
-349.86%
|
2.17
+156.07%
|
-3.86
|
0.00
|
| Other Special Charges |
|
—
|
-2.17
-156.07%
|
3.86
|
—
|
| Write Off |
|
5.41
|
0.00
|
—
|
—
|
| Net Income |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Pretax Income |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Net Non Operating Interest Income Expense |
|
-16.20
-61.29%
|
-10.04
-310.50%
|
-2.45
-8537.93%
|
0.03
|
| Interest Expense Non Operating |
|
16.59
+54.44%
|
10.74
+309.06%
|
2.63
|
0.00
|
| Net Interest Income |
|
-16.20
-61.29%
|
-10.04
-310.50%
|
-2.45
-8537.93%
|
0.03
|
| Interest Expense |
|
16.59
+54.44%
|
10.74
+309.06%
|
2.63
|
0.00
|
| Interest Income Non Operating |
|
0.39
-44.33%
|
0.70
+289.39%
|
0.18
+517.24%
|
0.03
|
| Interest Income |
|
0.39
-44.33%
|
0.70
+289.39%
|
0.18
+517.24%
|
0.03
|
| Other Income Expense |
|
-126.38
-476.51%
|
33.56
+230.56%
|
-25.71
|
—
|
| Other Non Operating Income Expenses |
|
-120.96
-485.24%
|
31.40
+243.74%
|
-21.84
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Net Income From Continuing Operation Net Minority Interest |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Net Income From Continuing And Discontinued Operation |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Net Income Continuous Operations |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Normalized Income |
|
-168.39
-698.72%
|
-21.08
+67.66%
|
-65.18
-76.56%
|
-36.92
|
| Net Income Common Stockholders |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Diluted EPS |
|
-4.80
-439.33%
|
-0.89
+53.40%
|
-1.91
-76.85%
|
-1.08
|
| Basic EPS |
|
-4.80
-823.08%
|
-0.52
+72.77%
|
-1.91
-76.85%
|
-1.08
|
| Basic Average Shares |
|
36.24
+0.22%
|
36.16
+0.24%
|
36.08
+5.19%
|
34.29
|
| Diluted Average Shares |
|
36.24
-38.64%
|
59.06
+63.71%
|
36.08
+5.19%
|
34.29
|
| Diluted NI Availto Com Stockholders |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
76.88
-11.05%
|
86.44
-12.12%
|
98.36
+2.64%
|
95.83
|
| Current Assets |
|
10.67
-5.66%
|
11.31
-40.95%
|
19.15
-29.19%
|
27.05
|
| Cash Cash Equivalents And Short Term Investments |
|
8.69
-6.49%
|
9.29
-31.29%
|
13.52
-8.95%
|
14.85
|
| Cash And Cash Equivalents |
|
8.69
-6.49%
|
9.29
-31.29%
|
13.52
-8.95%
|
14.85
|
| Receivables |
|
0.47
-36.56%
|
0.74
-77.88%
|
3.36
-60.58%
|
8.53
|
| Other Receivables |
|
0.47
-36.56%
|
0.74
-77.88%
|
3.36
-60.58%
|
8.53
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.51
+18.46%
|
1.27
-43.80%
|
2.27
-38.18%
|
3.66
|
| Total Non Current Assets |
|
66.21
-11.87%
|
75.13
-5.15%
|
79.21
+15.16%
|
68.79
|
| Net PPE |
|
46.10
-16.06%
|
54.93
-4.10%
|
57.28
+22.77%
|
46.65
|
| Gross PPE |
|
60.15
-11.65%
|
68.07
-1.48%
|
69.10
+19.64%
|
57.76
|
| Accumulated Depreciation |
|
-14.04
-6.80%
|
-13.15
-11.21%
|
-11.82
-6.47%
|
-11.10
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.29
+1.73%
|
1.27
+1.12%
|
1.25
-0.87%
|
1.27
|
| Other Properties |
|
55.05
-12.62%
|
63.00
-2.16%
|
64.39
+21.40%
|
53.04
|
| Leases |
|
3.80
+0.00%
|
3.80
+10.30%
|
3.45
+0.00%
|
3.45
|
| Goodwill And Other Intangible Assets |
|
13.75
+0.00%
|
13.75
+0.00%
|
13.75
+0.00%
|
13.75
|
| Goodwill |
|
3.49
+0.00%
|
3.49
+0.00%
|
3.49
+0.00%
|
3.49
|
| Other Intangible Assets |
|
10.26
+0.00%
|
10.26
+0.00%
|
10.26
+0.00%
|
10.26
|
| Other Non Current Assets |
|
6.36
-1.43%
|
6.46
-21.18%
|
8.19
-2.37%
|
8.39
|
| Total Liabilities Net Minority Interest |
|
295.48
+119.76%
|
134.46
+3.09%
|
130.43
+118.27%
|
59.75
|
| Current Liabilities |
|
8.95
-81.46%
|
48.25
+193.11%
|
16.46
-33.82%
|
24.87
|
| Payables And Accrued Expenses |
|
1.71
-17.03%
|
2.06
-63.88%
|
5.69
-5.72%
|
6.03
|
| Payables |
|
0.92
+20.23%
|
0.77
-51.67%
|
1.58
-5.54%
|
1.68
|
| Accounts Payable |
|
0.92
+20.23%
|
0.77
-51.67%
|
1.58
-5.54%
|
1.68
|
| Current Accrued Expenses |
|
0.78
-39.18%
|
1.29
-68.59%
|
4.10
-5.79%
|
4.36
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.19
-3.90%
|
2.28
+196.88%
|
0.77
-57.99%
|
1.83
|
| Current Debt And Capital Lease Obligation |
|
4.56
-89.48%
|
43.38
+357.60%
|
9.48
-44.27%
|
17.01
|
| Current Debt |
|
—
|
38.95
|
—
|
—
|
| Other Current Borrowings |
|
—
|
38.95
|
—
|
—
|
| Current Capital Lease Obligation |
|
4.56
+3.00%
|
4.43
-53.26%
|
9.48
-44.27%
|
17.01
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
0.49
-7.94%
|
0.53
+1.15%
|
0.52
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
286.53
+232.38%
|
86.21
-24.36%
|
113.97
+226.73%
|
34.88
|
| Long Term Debt And Capital Lease Obligation |
|
283.45
+240.98%
|
83.13
-25.03%
|
110.89
+248.67%
|
31.80
|
| Long Term Debt |
|
256.92
+363.46%
|
55.44
-32.65%
|
82.31
|
—
|
| Long Term Capital Lease Obligation |
|
26.53
-4.19%
|
27.69
-3.11%
|
28.58
-10.13%
|
31.80
|
| Non Current Deferred Liabilities |
|
3.08
+0.00%
|
3.08
+0.00%
|
3.08
+0.00%
|
3.08
|
| Non Current Deferred Taxes Liabilities |
|
3.08
+0.00%
|
3.08
+0.00%
|
3.08
+0.00%
|
3.08
|
| Stockholders Equity |
|
-218.60
-355.23%
|
-48.02
-49.76%
|
-32.06
-188.87%
|
36.08
|
| Common Stock Equity |
|
-218.60
-355.23%
|
-48.02
-49.76%
|
-32.06
-188.87%
|
36.08
|
| Capital Stock |
|
0.36
+0.55%
|
0.36
+0.28%
|
0.36
+0.00%
|
0.36
|
| Common Stock |
|
0.36
+0.55%
|
0.36
+0.28%
|
0.36
+0.00%
|
0.36
|
| Share Issued |
|
36.43
+0.69%
|
36.18
+0.17%
|
36.12
-0.06%
|
36.14
|
| Ordinary Shares Number |
|
36.43
+0.69%
|
36.18
+0.17%
|
36.12
-0.06%
|
36.14
|
| Additional Paid In Capital |
|
282.57
+1.15%
|
279.35
+1.07%
|
276.39
+0.33%
|
275.49
|
| Retained Earnings |
|
-501.53
-53.03%
|
-327.74
-6.13%
|
-308.82
-28.80%
|
-239.77
|
| Total Equity Gross Minority Interest |
|
-218.60
-355.23%
|
-48.02
-49.76%
|
-32.06
-188.87%
|
36.08
|
| Total Capitalization |
|
38.33
+416.72%
|
7.42
-85.24%
|
50.24
+39.25%
|
36.08
|
| Working Capital |
|
1.72
+104.66%
|
-36.94
-1473.27%
|
2.69
+23.74%
|
2.17
|
| Invested Capital |
|
38.33
-17.35%
|
46.37
-7.70%
|
50.24
+39.25%
|
36.08
|
| Total Debt |
|
288.02
+127.66%
|
126.52
+5.10%
|
120.37
+146.59%
|
48.81
|
| Net Debt |
|
248.23
+191.70%
|
85.10
+23.72%
|
68.78
|
—
|
| Capital Lease Obligations |
|
31.10
-3.20%
|
32.12
-15.60%
|
38.06
-22.02%
|
48.81
|
| Net Tangible Assets |
|
-232.34
-276.17%
|
-61.77
-34.83%
|
-45.81
-305.12%
|
22.33
|
| Tangible Book Value |
|
-232.34
-276.17%
|
-61.77
-34.83%
|
-45.81
-305.12%
|
22.33
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-25.76
+31.39%
|
-37.55
+20.82%
|
-47.42
-46.00%
|
-32.48
|
| Cash Flow From Continuing Operating Activities |
|
-25.76
+31.39%
|
-37.55
+20.82%
|
-47.42
-46.00%
|
-32.48
|
| Net Income From Continuing Operations |
|
-173.80
-818.79%
|
-18.92
+72.60%
|
-69.05
-87.03%
|
-36.92
|
| Depreciation Amortization Depletion |
|
1.53
+15.55%
|
1.32
+36.32%
|
0.97
+8.97%
|
0.89
|
| Depreciation |
|
1.53
+15.55%
|
1.32
|
—
|
0.89
|
| Depreciation And Amortization |
|
1.53
+15.55%
|
1.32
+36.32%
|
0.97
+8.97%
|
0.89
|
| Other Non Cash Items |
|
139.90
+852.61%
|
-18.59
-173.14%
|
25.41
|
—
|
| Stock Based Compensation |
|
2.61
-9.78%
|
2.89
+208.42%
|
0.94
-69.79%
|
3.10
|
| Asset Impairment Charge |
|
5.41
|
—
|
—
|
—
|
| Operating Gains Losses |
|
—
|
-2.17
-154.92%
|
3.94
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.08
|
0.00
|
| Change In Working Capital |
|
-1.41
+32.73%
|
-2.10
+78.24%
|
-9.65
-2297.27%
|
0.44
|
| Change In Receivables |
|
—
|
—
|
—
|
1.05
|
| Change In Prepaid Assets |
|
0.04
-99.24%
|
5.11
+5.80%
|
4.83
+162.99%
|
-7.66
|
| Change In Payables And Accrued Expense |
|
-0.42
+81.14%
|
-2.24
-119.69%
|
-1.02
-122.90%
|
4.46
|
| Change In Accrued Expense |
|
-0.09
-105.89%
|
1.51
+242.64%
|
-1.06
-233.67%
|
0.79
|
| Change In Payable |
|
-0.33
+91.11%
|
-3.75
-9728.21%
|
0.04
-98.94%
|
3.67
|
| Change In Account Payable |
|
-0.33
+91.11%
|
-3.75
-9728.21%
|
0.04
-98.94%
|
3.67
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
3.64
|
| Change In Other Current Liabilities |
|
-1.03
+79.28%
|
-4.96
+63.11%
|
-13.45
-469.23%
|
3.64
|
| Investing Cash Flow |
|
-0.54
+71.15%
|
-1.88
+76.90%
|
-8.13
-267.89%
|
-2.21
|
| Cash Flow From Continuing Investing Activities |
|
-0.54
+71.15%
|
-1.88
+76.90%
|
-8.13
-267.89%
|
-2.21
|
| Net PPE Purchase And Sale |
|
-0.54
+71.15%
|
-1.88
+76.90%
|
-8.13
-267.89%
|
-2.21
|
| Purchase Of PPE |
|
-0.54
+71.15%
|
-1.88
+76.93%
|
-8.14
-268.34%
|
-2.21
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Capital Expenditure |
|
-0.54
+71.15%
|
-1.88
+76.93%
|
-8.14
-268.34%
|
-2.21
|
| Financing Cash Flow |
|
25.61
-26.73%
|
34.96
-35.25%
|
53.99
+22.66%
|
44.02
|
| Cash Flow From Continuing Financing Activities |
|
25.61
-26.73%
|
34.96
-35.25%
|
53.99
+22.66%
|
44.02
|
| Net Issuance Payments Of Debt |
|
25.00
-28.34%
|
34.89
-35.42%
|
54.03
|
0.00
|
| Issuance Of Debt |
|
25.00
-28.34%
|
34.89
-35.42%
|
54.03
|
0.00
|
| Long Term Debt Issuance |
|
25.00
-28.34%
|
34.89
-35.42%
|
54.03
|
0.00
|
| Net Long Term Debt Issuance |
|
25.00
-28.34%
|
34.89
-35.42%
|
54.03
|
0.00
|
| Net Common Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
44.39
|
| Proceeds From Stock Option Exercised |
|
0.66
+406.15%
|
0.13
+2500.00%
|
0.01
-96.00%
|
0.12
|
| Net Other Financing Charges |
|
-0.05
+24.59%
|
-0.06
-41.86%
|
-0.04
+91.40%
|
-0.50
|
| Changes In Cash |
|
-0.69
+84.50%
|
-4.47
-185.02%
|
-1.57
-116.83%
|
9.32
|
| Beginning Cash Position |
|
14.77
-23.24%
|
19.24
-7.54%
|
20.81
+81.16%
|
11.49
|
| End Cash Position |
|
14.08
-4.69%
|
14.77
-23.24%
|
19.24
-7.54%
|
20.81
|
| Free Cash Flow |
|
-26.30
+33.29%
|
-39.43
+29.04%
|
-55.57
-60.17%
|
-34.69
|
| Common Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
44.39
|
| Interest Paid CFO |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
—
|
—
|
0.00
-100.00%
|
44.39
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 10-K2026-03-25 View
- 8-K2026-03-25 View
- 8-K2026-03-19 View
- 42026-03-17 View
- 42026-03-17 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 8-K2026-02-23 View
- 8-K2026-01-26 View
- 8-K2026-01-13 View
- 8-K2025-12-01 View
- 10-Q2025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|